This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hegde, M. Articles by Richards, C. Search for Related Content PubMed PubMed Citation Articles by Hegde, M. Articles by Richards, C.

JMD 2005, Vol. 7, No. 4
Copyright © 2005 American Society for Investigative Pathology & Association for Molecular Pathology

Assay Validation for Identification of Hereditary Nonpolyposis Colon Cancer-Causing Mutations in Mismatch Repair Genes MLH1, MSH2, and MSH6

Madhuri Hegde^*, Maria Blazo^*, Belinda Chong^*, Tom Prior and Carolyn Richards^*

From The Diagnostic Sequencing Laboratory, * Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, Texas; and the Ohio State University, Department of Pathology, Columbus, Ohio

Hereditary nonpolyposis colon cancer (HNPCC, Online Mendelian Inheritance in Man (OMIM) 114500) is an autosomal dominant disorder that is genetically heterogeneous because of underlying mutations in mismatch repair genes, primarily MLH1, MSH2, and MSH6. One challenge to correctly diagnosing HNPCC is that the large size of the causative genes makes identification of mutations both labor intensive and expensive. We evaluated the usefulness of denaturing high performance liquid chromatography (DHPLC) for scanning mismatch repair genes (MLH1, MSH2, and MSH6) for point mutations, small deletions, and insertions. Our assay consisted of 51 sets of primers designed to amplify all exons of these genes. All polymerase chain reaction reactions were amplified simultaneously using the same reaction conditions in a 96-well format. The amplified products were analyzed by DHPLC across a range of optimum temperatures for partial fragment denaturation based on the melting profile of each specific fragment. DNA specimens from 23 previously studied HNPCC patients were analyzed by DHPLC, and all mutations were correctly identified and confirmed by sequence analysis. Here, we present our validation studies of the DHPLC platform for HNPCC mutation analysis and compare its merits with other scanning technologies. This approach provides greater sensitivity and more directed molecular analysis for clinical testing in HNPCC.

This article has been cited by other articles:

				M. P. Hitchins, J. J.L. Wong, G. Suthers, C. M. Suter, D. I.K. Martin, N. J. Hawkins, and R. L. Ward Inheritance of a Cancer-Associated MLH1 Germ-Line Epimutation N. Engl. J. Med., February 15, 2007; 356(7): 697 - 705. [Abstract] [Full Text] [PDF]